Viral hepatitis

Arie Regev, Eugene R Schiff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Viral hepatitis is still one of the most common causes of acute and chronic liver disease worldwide. Major advances have been made in our knowledge of these diseases, many during the past year. Molecular biology and clinical studies have improved our understanding of the mechanisms of antiviral drugs, as well as viral resistance to therapy. The risks of hepatitis A in patients with chronic liver disease have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven. Aggressive combination therapy has emerged as a promising strategy for chronic hepatitis B and C, and techniques for immune prophylaxis for hepatitis B are being improved. Liver transplantation has become routine for end-stage hepatitis B virus liver disease, and new strategies to prevent and treat recurrence are being explored. This review discusses the recent advances in our knowledge of hepatitis viruses A through G, focusing on the literature of the past year.

Original languageEnglish
Pages (from-to)234-239
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume15
Issue number3
DOIs
StatePublished - Jun 14 1999

Fingerprint

Hepatitis
Liver Diseases
Chronic Disease
Hepatitis A Vaccines
Hepatitis A virus
Hepatitis A
Chronic Hepatitis B
Chronic Hepatitis C
Virus Diseases
Hepatitis B
Hepatitis B virus
Liver Transplantation
Antiviral Agents
Molecular Biology
Recurrence
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Viral hepatitis. / Regev, Arie; Schiff, Eugene R.

In: Current Opinion in Gastroenterology, Vol. 15, No. 3, 14.06.1999, p. 234-239.

Research output: Contribution to journalArticle

Regev, Arie ; Schiff, Eugene R. / Viral hepatitis. In: Current Opinion in Gastroenterology. 1999 ; Vol. 15, No. 3. pp. 234-239.
@article{d9b48272bebe444fb1fb3fab9c1a1b84,
title = "Viral hepatitis",
abstract = "Viral hepatitis is still one of the most common causes of acute and chronic liver disease worldwide. Major advances have been made in our knowledge of these diseases, many during the past year. Molecular biology and clinical studies have improved our understanding of the mechanisms of antiviral drugs, as well as viral resistance to therapy. The risks of hepatitis A in patients with chronic liver disease have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven. Aggressive combination therapy has emerged as a promising strategy for chronic hepatitis B and C, and techniques for immune prophylaxis for hepatitis B are being improved. Liver transplantation has become routine for end-stage hepatitis B virus liver disease, and new strategies to prevent and treat recurrence are being explored. This review discusses the recent advances in our knowledge of hepatitis viruses A through G, focusing on the literature of the past year.",
author = "Arie Regev and Schiff, {Eugene R}",
year = "1999",
month = "6",
day = "14",
doi = "10.1097/00001574-199905000-00008",
language = "English",
volume = "15",
pages = "234--239",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Viral hepatitis

AU - Regev, Arie

AU - Schiff, Eugene R

PY - 1999/6/14

Y1 - 1999/6/14

N2 - Viral hepatitis is still one of the most common causes of acute and chronic liver disease worldwide. Major advances have been made in our knowledge of these diseases, many during the past year. Molecular biology and clinical studies have improved our understanding of the mechanisms of antiviral drugs, as well as viral resistance to therapy. The risks of hepatitis A in patients with chronic liver disease have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven. Aggressive combination therapy has emerged as a promising strategy for chronic hepatitis B and C, and techniques for immune prophylaxis for hepatitis B are being improved. Liver transplantation has become routine for end-stage hepatitis B virus liver disease, and new strategies to prevent and treat recurrence are being explored. This review discusses the recent advances in our knowledge of hepatitis viruses A through G, focusing on the literature of the past year.

AB - Viral hepatitis is still one of the most common causes of acute and chronic liver disease worldwide. Major advances have been made in our knowledge of these diseases, many during the past year. Molecular biology and clinical studies have improved our understanding of the mechanisms of antiviral drugs, as well as viral resistance to therapy. The risks of hepatitis A in patients with chronic liver disease have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven. Aggressive combination therapy has emerged as a promising strategy for chronic hepatitis B and C, and techniques for immune prophylaxis for hepatitis B are being improved. Liver transplantation has become routine for end-stage hepatitis B virus liver disease, and new strategies to prevent and treat recurrence are being explored. This review discusses the recent advances in our knowledge of hepatitis viruses A through G, focusing on the literature of the past year.

UR - http://www.scopus.com/inward/record.url?scp=0033054376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033054376&partnerID=8YFLogxK

U2 - 10.1097/00001574-199905000-00008

DO - 10.1097/00001574-199905000-00008

M3 - Article

VL - 15

SP - 234

EP - 239

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -